WaveMan · Company
ODYY · Odyssey Health, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ODYY Odyssey Health (ODYY) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001626644
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2019-08-01 to 2020-07-31
History
FY Jul 2025$0
FY Jul 2024$0
FY Jul 2023$0
FY Jul 2022$0
FY Jul 2021$0
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 20250.18x
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.79x
TTM operating cash flow over long-term 2021-07-31 (57 months older than the period end) plus current 2022-07-31 (45 months older than the period end)
History
FY Jul 2025-0.29x
FY Jul 2024-1.03x
FY Jul 2023-1.25x
FY Jul 2022-1.25x
FY Jul 2021n/a
Apr 2026-0.79x
Jan 2026-0.53x
Oct 2025-0.32x
Jul 2025-0.29x
Apr 2025-0.31x
Jan 2025-0.46x
Oct 2024-1.19x
Jul 2024-1.03x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025-195.2%
Jan 2025-1,343%
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1,327%
TTM net income over average of 2025-04-30 and 2026-04-30
History
FY Jul 2025-548.1%
FY Jul 2024-161.7%
FY Jul 2023-1,154%
FY Jul 2022-1,431%
FY Jul 2021-4,715%
Apr 2026-1,327%
Jan 2026-928.7%
Oct 2025-498.2%
Jul 2025-548.1%
Apr 2025-207.1%
Jan 2025-207.0%
Oct 2024-277.7%
Jul 2024-161.7%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.0M
market value at close 2026-10-09 on 2026-06-12 shares, plus long-term 2021-07-31 (57 months older than the period end) plus current 2022-07-31 (45 months older than the period end), minus cash 2025-04-30
History
FY Jul 2025$3.3M
FY Jul 2024$5.3M
FY Jul 2023$12.1M
FY Jul 2022$17.1M
FY Jul 2021$49.1M
Apr 2026$6.9M
Jan 2026$8.4M
Oct 2025$8.6M
Jul 2025$3.3M
Apr 2025$1.8M
Jan 2025$3.3M
Oct 2024$3.0M
Jul 2024$5.3M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Jul 2025n/a
FY Jul 2024n/a
FY Jul 2023n/a
FY Jul 2022n/a
FY Jul 2021n/a
Apr 2026n/a
Jan 2026n/a
Oct 2025n/a
Jul 2025n/a
Apr 2025n/a
Jan 2025n/a
Oct 2024n/a
Jul 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

ODYY Stock Sonar score 2/7 axes

Find similar shapesCompare
Financial health
35
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.79x · 35 pct, sector of 150
Risk and compliance
92
Inputs
  • Short interest, % of float+0.1% · 91 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.4% · 92 pct, sector of 198
5 not measured: Profitability, Growth, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
below 88% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ODYY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-91.1%12M
-96%-58%-21%+17%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

Odyssey Health insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Odyssey Health, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns ODYY: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ODYY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ODYY planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-072024-072023-072022-07
Operating income$-1.0M$-2.1M$-5.3M$-8.1M
Net income$-1.7M$-842.3K$-5.9M$-8.4M
EPS (diluted)-0.02-0.01-0.07-0.09
Operating cash flow$-347.4K$-1.2M$-1.5M$-1.5M
Cashn/an/a$36.9K$72.5K
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies